IS7948A - Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra - Google Patents

Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra

Info

Publication number
IS7948A
IS7948A IS7948A IS7948A IS7948A IS 7948 A IS7948 A IS 7948A IS 7948 A IS7948 A IS 7948A IS 7948 A IS7948 A IS 7948A IS 7948 A IS7948 A IS 7948A
Authority
IS
Iceland
Prior art keywords
phosphonooxyquinazoline
derivatives
pharmaceutical uses
pharmaceutical
phosphonooxyquinazoline derivatives
Prior art date
Application number
IS7948A
Other languages
English (en)
Other versions
IS2504B (is
Inventor
Murdoch Heron Nicola
Henri Jung Frederic
Rene Pasquet Georges
Austen Mortlock Andrew
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7948A publication Critical patent/IS7948A/is
Publication of IS2504B publication Critical patent/IS2504B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS7948A 2002-12-24 2005-07-20 Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra IS2504B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02293238 2002-12-24
EP03291315 2003-06-02
PCT/GB2003/005613 WO2004058781A1 (en) 2002-12-24 2003-12-22 Phosphonooxy quinazoline derivatives and their pharmaceutical use

Publications (2)

Publication Number Publication Date
IS7948A true IS7948A (is) 2005-07-20
IS2504B IS2504B (is) 2009-04-15

Family

ID=32683824

Family Applications (2)

Application Number Title Priority Date Filing Date
IS7948A IS2504B (is) 2002-12-24 2005-07-20 Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
IS8714A IS2884B (is) 2002-12-24 2008-02-13 Kínasólínafleiður

Family Applications After (1)

Application Number Title Priority Date Filing Date
IS8714A IS2884B (is) 2002-12-24 2008-02-13 Kínasólínafleiður

Country Status (29)

Country Link
US (4) US7528121B2 (is)
EP (2) EP1847539B1 (is)
JP (3) JP4422102B2 (is)
KR (1) KR101010299B1 (is)
AR (2) AR042668A1 (is)
AT (2) ATE438644T1 (is)
AU (1) AU2003290313B2 (is)
BR (1) BRPI0317717B8 (is)
CA (1) CA2511613C (is)
CL (1) CL2003002731A1 (is)
CY (2) CY1107775T1 (is)
DE (2) DE60328735D1 (is)
DK (2) DK1847539T3 (is)
ES (2) ES2329623T3 (is)
IL (2) IL169112A (is)
IS (2) IS2504B (is)
MX (1) MXPA05006918A (is)
MY (2) MY147761A (is)
NO (2) NO335193B1 (is)
NZ (1) NZ540698A (is)
PL (2) PL223998B1 (is)
PT (2) PT1847539E (is)
RU (3) RU2350611C1 (is)
SA (1) SA04240504B1 (is)
SI (2) SI1578755T1 (is)
TW (2) TWI393710B (is)
UA (1) UA83814C2 (is)
UY (1) UY28149A1 (is)
WO (1) WO2004058781A1 (is)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1463506T1 (sl) * 2001-12-24 2010-01-29 Astrazeneca Ab Substituirani kinazolinski derivati kot inhibitorji kinaz Aurora
US7407946B2 (en) * 2002-12-24 2008-08-05 Astrazeneca Ab Quinazoline compounds
ATE438644T1 (de) * 2002-12-24 2009-08-15 Astrazeneca Ab Chinazolinderivate
BRPI0409427A (pt) * 2003-04-16 2006-04-18 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
ATE534649T1 (de) * 2003-05-15 2011-12-15 Arqule Inc Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
US20090036474A1 (en) * 2004-10-12 2009-02-05 Patrick Ple Quinazoline derivatives for use against cancer
MX2007004403A (es) 2004-10-12 2007-04-27 Astrazeneca Ab Derivados de quinazolina.
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
EP2258704A1 (en) * 2004-10-19 2010-12-08 ArQule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US7501430B2 (en) * 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
GB0609617D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
EP2262796A1 (en) * 2008-03-04 2010-12-22 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
AU2009241469B2 (en) 2008-04-30 2015-05-07 National Health Research Institutes Fused bicyclic pyrimidine compounds as Aurora kinase inhibitors
EP2291376A2 (en) * 2008-07-03 2011-03-09 Merck Patent GmbH Naphthyridininones as aurora kinase inhibitors
AU2009322158A1 (en) * 2008-12-05 2010-06-10 Arqule, Inc. RAF inhibitors and their uses
BRPI0923504A2 (pt) 2008-12-11 2020-05-26 Axcentua Pharmaceuticals Ab Formas cristalinas de genisteína.
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
JP5738196B2 (ja) 2008-12-22 2015-06-17 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
WO2014130612A1 (en) 2013-02-20 2014-08-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
JP6301374B2 (ja) * 2013-02-21 2018-03-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのキナゾリン類
LT3046584T (lt) 2013-09-16 2017-10-10 Astrazeneca Ab Terapinės polimerinės nanodalelės ir jų gamybos būdai ir panaudojimas
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN108530458A (zh) 2013-11-01 2018-09-14 卡拉制药公司 治疗化合物的结晶形式及其用途
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
US20180207173A1 (en) 2015-07-21 2018-07-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
PL3678668T3 (pl) 2017-09-08 2024-06-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory enpp1 i ich zastosowanie w leczeniu nowotworu
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en) 2021-03-10 2022-09-15 Astrazeneca Ab Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU2737295A (en) 1994-06-09 1996-01-04 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (is) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
CA2239692C (en) 1995-12-18 2008-12-16 Sugen, Inc. Diagnosis and treatment of aur-1 and/or aur-2 related disorders
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ATE294796T1 (de) 1998-10-08 2005-05-15 Astrazeneca Ab Chinazolin derivate
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
AU7301000A (en) 1999-09-21 2001-04-24 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
EP1299381B1 (en) * 2000-06-28 2008-05-07 AstraZeneca AB Substituted quinazoline derivatives and their use as inhibitors
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
ATE402169T1 (de) * 2000-08-18 2008-08-15 Millennium Pharm Inc Quinazolin-derivate als kinase inhibitoren
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1408980A4 (en) * 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
SI1463506T1 (sl) * 2001-12-24 2010-01-29 Astrazeneca Ab Substituirani kinazolinski derivati kot inhibitorji kinaz Aurora
US7407946B2 (en) * 2002-12-24 2008-08-05 Astrazeneca Ab Quinazoline compounds
ATE438644T1 (de) * 2002-12-24 2009-08-15 Astrazeneca Ab Chinazolinderivate
BRPI0409427A (pt) * 2003-04-16 2006-04-18 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo

Also Published As

Publication number Publication date
HK1111417A1 (en) 2008-08-08
TWI393710B (zh) 2013-04-21
US9018191B2 (en) 2015-04-28
DE60315892D1 (de) 2007-10-04
PL221490B1 (pl) 2016-04-29
SA04240504A (ar) 2005-12-03
EP1578755B1 (en) 2007-08-22
BR0317717A (pt) 2005-11-22
NO335446B1 (no) 2014-12-15
AU2003290313A1 (en) 2004-07-22
US20100069412A1 (en) 2010-03-18
NO335193B1 (no) 2014-10-20
KR20050088333A (ko) 2005-09-05
IS8714A (is) 2008-02-13
JP4906608B2 (ja) 2012-03-28
ES2290529T3 (es) 2008-02-16
CA2511613C (en) 2012-10-02
TW200510342A (en) 2005-03-16
IL185176A0 (en) 2007-12-03
CY1107775T1 (el) 2013-06-19
DE60315892T2 (de) 2008-08-14
NO20131444L (no) 2005-08-03
JP4422102B2 (ja) 2010-02-24
ATE370958T1 (de) 2007-09-15
CA2511613A1 (en) 2004-07-15
NO20052855L (no) 2005-08-03
RU2005123485A (ru) 2006-03-10
US9567358B2 (en) 2017-02-14
PT1578755E (pt) 2007-10-19
CY1109479T1 (el) 2014-08-13
TWI336327B (en) 2011-01-21
UY28149A1 (es) 2004-07-30
CL2003002731A1 (es) 2005-01-07
DK1578755T3 (da) 2007-11-12
UA83814C2 (ru) 2008-08-26
SA04240504B1 (ar) 2008-04-01
NZ540698A (en) 2008-05-30
NO20052855D0 (no) 2005-06-13
US20140162984A1 (en) 2014-06-12
PT1847539E (pt) 2009-10-06
JP2009046514A (ja) 2009-03-05
KR101010299B1 (ko) 2011-01-25
PL223998B1 (pl) 2016-11-30
EP1847539B1 (en) 2009-08-05
BRPI0317717B8 (pt) 2021-05-25
MXPA05006918A (es) 2005-08-18
RU2357971C2 (ru) 2009-06-10
AU2003290313B2 (en) 2007-05-10
TW201102369A (en) 2011-01-16
ATE438644T1 (de) 2009-08-15
US20150307534A1 (en) 2015-10-29
MY147761A (en) 2013-01-31
US8268841B2 (en) 2012-09-18
MY136174A (en) 2008-08-29
RU2007121850A (ru) 2008-12-20
ES2329623T3 (es) 2009-11-27
DK1847539T3 (da) 2009-11-09
US20060116357A1 (en) 2006-06-01
IL169112A (en) 2010-12-30
SI1847539T1 (sl) 2010-01-29
WO2004058781A1 (en) 2004-07-15
RU2350611C1 (ru) 2009-03-27
US7528121B2 (en) 2009-05-05
PL377680A1 (pl) 2006-02-06
IS2504B (is) 2009-04-15
IL185176A (en) 2011-10-31
SI1578755T1 (sl) 2007-12-31
JP4503090B2 (ja) 2010-07-14
EP1578755A1 (en) 2005-09-28
AR042668A1 (es) 2005-06-29
AR057753A2 (es) 2007-12-19
HK1080481A1 (en) 2006-04-28
EP1847539A1 (en) 2007-10-24
DE60328735D1 (de) 2009-09-17
JP2006512418A (ja) 2006-04-13
BRPI0317717B1 (pt) 2017-12-19
IS2884B (is) 2014-06-15
IL169112A0 (en) 2009-02-11
JP2007326862A (ja) 2007-12-20
PL412704A1 (pl) 2015-10-12

Similar Documents

Publication Publication Date Title
IS7948A (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
IS2599B (is) 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
DK1673349T3 (da) Benzimidazolderivater: fremstilling og farmaceutiske anvendelser
NO20052524D0 (no) Aminerte isofiavonoidderivater og anvendelse derav
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
KR20050009999A (ko) 약제학적 제제
NO20041975D0 (no) Bicyklisk oksopyridin og oksopyrimidinderivater
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
IS3007B (is) Ónæmisbælandi efnasambönd og efnablöndur
PT1501534E (pt) Formulacoes farmaceuticas
DK1465615T3 (da) Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
DK1575618T3 (da) Dispergerbare farmaceutiske kombinationer
DE60319951D1 (de) Aminocyclische substituierte pyrrolopyrimidinderivate und pyrrolopyridinderivate
IS7594A (is) Laxófoxifen tafla og húðun hennar
DK1354873T3 (da) Perindoaprilsalt og farmaceutiske sammensætninger indeholdende dette
DK1513836T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
NO20055173D0 (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
NO20054135D0 (no) Kipolinon/benzoksazin derivater og anvendelser derav
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20054095D0 (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater
NO20043333L (no) Farmasoytiske parvastatinformuleringer og fremgangsmater for anvendelse av dem
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir